Cytophage Technologies (TSXV:CYTO) Equity-to-Asset : 0.99 (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cytophage Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$5.41 Mil. Cytophage Technologies's Total Assets for the quarter that ended in Dec. 2023 was C$5.46 Mil.

The historical rank and industry rank for Cytophage Technologies's Equity-to-Asset or its related term are showing as below:

TSXV:CYTO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.94 Med: 0.95 Max: 0.99
Current: 0.99

During the past 3 years, the highest Equity to Asset Ratio of Cytophage Technologies was 0.99. The lowest was 0.94. And the median was 0.95.

TSXV:CYTO's Equity-to-Asset is ranked better than
99.42% of 1558 companies
in the Biotechnology industry
Industry Median: 0.67 vs TSXV:CYTO: 0.99

Cytophage Technologies Equity-to-Asset Historical Data

The historical data trend for Cytophage Technologies's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Equity-to-Asset Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Equity-to-Asset

0.95

0.94

0.99

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
Equity-to-Asset	0.95	-	0.94	0.85	0.99

Competitive Comparison of Cytophage Technologies's Equity-to-Asset

For the Biotechnology subindustry, Cytophage Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytophage Technologies's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's Equity-to-Asset falls into.

Cytophage Technologies Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Cytophage Technologies's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	5.411	/	5.461
	=

Cytophage Technologies's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	5.411	/	5.461
	=

Cytophage Technologies (TSXV:CYTO) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Cytophage Technologies Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.